First Phase III Data For Inovio's Immunotherapy VGX-3100 Encouraging In Cervical Dysplasia
Withdrawals Affect ITT But Not mITT Analysis
Executive Summary
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.